Meeting
2015 ASCO Annual Meeting
Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients.
Authors
Soner Altiok
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Soner Altiok , Melanie Mediavilla Valera , Jenny Kreahling , David Noyes , Tiffany N Razabdouski , Nikoletta L. Kallinteris , Joseph Shan , Scott Joseph Antonia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3060)
DOI
10.1200/jco.2015.33.15_suppl.3060
Abstract #
3060
Poster Bd #
386
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
First Author: Jose Antonio Lopez Guerrero
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang
Poster
2018 ASCO Annual Meeting
Various checkpoint proteins, and tumor infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy.
First Author: Kazuhiro Mochizuki